Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1923)	10/3/2007 12:19:03 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

VER.L is bouncing back & is up 24% after it tanked 53% yesterday.<g> bigcharts.marketwatch.com VER was down after the FDA rejected its NDA for Frova, which is already approved and marketed for acute migraine & VER & ENDO wanted to have it approved for prevention of migraine associated with menstrual syndrome. VER was expecting a $40M milestone payment from Endo. The FDA's concerns were on potential cardiovascular side effects when Frova is used to prevent, rather than just treat, migraines. But some of the insiders were buying after yesterday's dip & VER still has plenty of room to run, if it can close the DG.(The H in 1999 was > 3000 <g>) bigcharts.marketwatch.com Bernard